Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2018

01-06-2018 | Brief Report

A novel patient-derived xenograft model for claudin-low triple-negative breast cancer

Authors: Margarite D. Matossian, Hope E. Burks, Annie C. Bowles, Steven Elliott, Van T. Hoang, Rachel A. Sabol, Nicholas C. Pashos, Benjamen O’Donnell, Kristin S. Miller, Bahia M. Wahba, Bruce A. Bunnell, Krzysztof Moroz, Arnold H. Zea, Steven D. Jones, Augusto C. Ochoa, Amir A. Al-Khami, Fokhrul Hossain, Adam I. Riker, Lyndsay V. Rhodes, Elizabeth C. Martin, Lucio Miele, Matthew E. Burow, Bridgette M. Collins-Burow

Published in: Breast Cancer Research and Treatment | Issue 2/2018

Login to get access

Abstract

Background

Triple-negative breast cancer (TNBC) subtypes are clinically aggressive and cannot be treated with targeted therapeutics commonly used in other breast cancer subtypes. The claudin-low (CL) molecular subtype of TNBC has high rates of metastases, chemoresistance and recurrence. There exists an urgent need to identify novel therapeutic targets in TNBC; however, existing models utilized in target discovery research are limited. Patient-derived xenograft (PDX) models have emerged as superior models for target discovery experiments because they recapitulate features of patient tumors that are limited by cell-line derived xenograft methods.

Methods

We utilize immunohistochemistry, qRT-PCR and Western Blot to visualize tumor architecture, cellular composition, genomic and protein expressions of a new CL-TNBC PDX model (TU-BcX-2O0). We utilize tissue decellularization techniques to examine extracellular matrix composition of TU-BcX-2O0.

Results

Our laboratory successfully established a TNBC PDX tumor, TU-BCX-2O0, which represents a CL-TNBC subtype and maintains this phenotype throughout subsequent passaging. We dissected TU-BCx-2O0 to examine aspects of this complex tumor that can be targeted by developing therapeutics, including the whole and intact breast tumor, specific cell populations within the tumor, and the extracellular matrix.

Conclusions

Here, we characterize a claudin-low TNBC patient-derived xenograft model that can be utilized for therapeutic research studies.
Appendix
Available only for authorised users
Literature
1.
Alteri R, Bertaut T, Brinton LA, Fedewa S, Freedman RA, Gansler T et al (2015) Breast cancer facts and figures 2015–2016. American Cancer Society Inc, Atlanta
2.
3.
Crown J, O’Shaughnessy J, Gullo G (2012) Emerging targeted therapies in triple-negative breast cancer. Ann Oncol 23(S6):vi56–vi65PubMed
4.
5.
Engebraaten O, Vollan HKM, Borresen-Dale A-L (2013) Triple-negative breast cancer and the need for new therapeutic targets. Am J Pathol 183(4):1064–1074CrossRefPubMed
6.
7.
Lehmann BD, Pietenpol JA (2014) Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol 232:142–150CrossRefPubMedPubMedCentral
8.
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig 121(7):2750–2767CrossRefPubMedPubMedCentral
9.
Sabatier R, Finetti P, Guille A, Adelaide J, Chaffanet M, Viens P, Birnbaum D, Bertucci F (2014) Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization. Mol Cancer 13:228CrossRefPubMedPubMedCentral
10.
11.
12.
Mayer IA, Abramson VG, Lehmann BD, Pientenpol JA (2014) New strategies for triple-negative breast cancer—deciphering the heterogeneity. Clin Cancer Res 20(4):782–790CrossRefPubMedPubMedCentral
13.
14.
Cifani P, Kirik U, Waldemarson S, James P (2015) Molecular portrait of breast-cancer-derived cell lines reveals poor similarity with tumors. J Proteome Res 14(7):2819–2827CrossRefPubMed
15.
Manning HC, Buck JR, Cook RS (2016) Mouse models of breast cancer: platforms for discovering precision imaging diagnostics and future cancer medicine. J Nucl Med 57(S1):60S–68SCrossRefPubMed
16.
Gillet JP, Clacagno AM, Varma S, Marino M, Green LJ, Vora MI et al (2011) Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci USA 108:18709–18713CrossRef
17.
18.
Hidalgo M, Amant F, Biankin AV, Budinska E, Byrne AT, Caldas C et al (2014) Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov 4:998CrossRefPubMedPubMedCentral
19.
Li G (2015) Patient-derived xenograft models for oncology drug discovery. J Cancer Meta Treat 1:8–15
20.
DeRose YS, Gligorich KM, Wang G, Georgelas A, Bowman P, Courdy SJ, Welm AL, Welm BE (2013) Patient-derived models of human breast cancer: protocols for in vitro and in vivo applications in tumor biology and translational medicine. Curr Protoc Pharmacol 14:14–23
21.
Julien S, Merino-Trigo A, Lacroix L, Pocard M, Goere D, Mariani P et al (2012) Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res 18(19):5314–5328CrossRefPubMed
22.
Jin K, Teng L, Shen Y, He K, Xu Z, Li G (2010) Patient-derived human tumor tissue xenografts in immunodeficient mice: a systematic review. Clin Transl Oncol 12:473CrossRefPubMed
23.
Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, Arcaroli JJ, Messersmith WA, Eckhardt SG (2012) Patient-derived xenografts as models for oncology drug development. Nat Rev Clin Oncol 9:338–350CrossRefPubMedPubMedCentral
24.
Whittle JR, Lewis MT, Lindeman GJ, Visvader JE (2015) Patient-derived xenograft models of breast cancer and their predictive power. Breast Cancer Res 17:17CrossRefPubMedPubMedCentral
25.
Landis MD, Lehmann BD, Pietenpol JA, Chang JC (2013) Patient-derived breast tumor xenografts facilitating personalized cancer therapy. Breast Cancer Res 15:201CrossRefPubMedPubMedCentral
26.
Bertotti A, Migliardi G, Galimi F, Sassi F, Tordi D, Isella C et al (2011) A molecularly annotated platform of patient-derived xenograft (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 1:508–523CrossRefPubMed
27.
Reyal F, Guyader C, Decraene C, Lucchesi C, Auger N, Assayag F et al (2011) Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res 14:R11CrossRef
28.
Eirew P, Steif A, Khattra J, Ha G, Yap D, Farahani H et al (2013) Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 518:422–426CrossRef
29.
Rhodes LV, Tate CR, Segar HC, Burks HE, Phamduy TB, Hoang V et al (2014) Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators. Breast Cancer Res Treat 145(3):593–604CrossRefPubMedPubMedCentral
30.
Pashos NC, Scarritt ME, Eagle ZR, Gimble JM, Chaffin AE, Bunnell BA (2017) Characterization of an acellular scaffold for a tissue engineering approach to the nipple-areolar complex reconstruction. Cells Tissues Org 203:183–193CrossRef
31.
Bonvillain RW, Scarritt ME, Pashos NC, Sullivan DE, Betancourt AM, Tsien F et al (2016) Characterization of Rhesus Macaque lung-resident multipotent stromal cells. Cell Gene Ther Insights 2(1):47–92
32.
33.
Jézéquel P, Loussouarn D, Charbonnel-Guérin C, Campion L, Vanier A, Gouraud W, Lasla H, Guette C, Valo I, Verriéle V, Campone M (2015) Gene-expression molecular subtyping of triple-negative breast cancer tumors: importance of immune response. Breast Cancer Res 17:43CrossRefPubMedPubMedCentral
34.
Lattouf R, Younes R, Lutomski D, Naaman N, Godeau G, Senni K, Changotade S (2014) Picosirius red staining: a useful tool to appraise collagen networks in normal and pathological tissues. J Histochem Cytochem 62(10):751–758CrossRefPubMed
35.
36.
Chanmee T, Ontong P, Konno K, Itano N (2014) Tumor-associated macrophages as major players in the tumor microenvironment. Cancers (Basel) 6(3):1670–1690CrossRef
37.
Yang L, Edwards CM, Mundy GR (2010) Gr-1+CD11b+ Myeloid-derived suppressor cells: formidable partners in tumor metastasis. J Bone Miner Res 25(8):1701–1706CrossRefPubMedPubMedCentral
38.
Gregory AD, Houghton AM (2011) Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res 71(7):2411–2416CrossRefPubMed
39.
Azab B, Bhatt VR, Phookan J, Murukutla S, Kohn N, Terjanian T, Widmann WD (2012) Usefulness of the Neutrophil-to-Lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol 19(1):217–224CrossRefPubMed
40.
Loch MM, Estrada J, Reske T, Li X, Chen V, Wu X (2013). Triple negative breast cancer in African American women: disparity between women in New Orleans versus Louisiana. Abstract: 2013 ASCO Annual Meeting
41.
Loch MM et al (2016) New Orleans has the highest incidence rates of triple negative breast cancer. Abstract: SABCS 2016
42.
Howlader N, Chen VW, Ries LAG, Loch MM, Lee R, DeSantis C et al (2014) Overview of breast cancer collaborative stage data items—their definitions, quality, usage and clinical implications: a review of SEER data for 2004–2010. Cancer 120(S23):3771–3780CrossRefPubMed
43.
Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, Becker M, Merk J (2008) Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res 14(20):6456–6468CrossRefPubMed
44.
Lin D, Wyatt AW, Xue H, Wang Y, Dong X, Haegert A et al (2014) High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Res 74(4):1272–1283CrossRefPubMed
Metadata
Title
A novel patient-derived xenograft model for claudin-low triple-negative breast cancer
Authors
Margarite D. Matossian
Hope E. Burks
Annie C. Bowles
Steven Elliott
Van T. Hoang
Rachel A. Sabol
Nicholas C. Pashos
Benjamen O’Donnell
Kristin S. Miller
Bahia M. Wahba
Bruce A. Bunnell
Krzysztof Moroz
Arnold H. Zea
Steven D. Jones
Augusto C. Ochoa
Amir A. Al-Khami
Fokhrul Hossain
Adam I. Riker
Lyndsay V. Rhodes
Elizabeth C. Martin
Lucio Miele
Matthew E. Burow
Bridgette M. Collins-Burow
Publication date
01-06-2018
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-4685-2

Other articles of this Issue 2/2018

Breast Cancer Research and Treatment 2/2018 Go to the issue

Clinical trial

Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I–III HER2-positive breast cancer

Clinical trial

Cross-reactivity between MUC1 antigen and MCA: false elevation of serum CA 15-3 level in pregnant and lactating women by Ma695–Ma552-based assay

Epidemiology

Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies

Clinical trial

Tamoxifen therapy improves overall survival in luminal A subtype of ductal carcinoma in situ: a study based on nationwide Korean Breast Cancer Registry database

Preclinical study

The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence

Review

Chronic postsurgical pain following breast reconstruction: a commentary and critique
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits